European Archives - Page 1040 of 1138 - European Medical Journal

EMJ

Overcoming acquired resistance to targeted therapies in lung cancer

At the European Cancer Congress (ECC) 2015, David Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, CO, explains that…

EMJ

The DETECT study: Personalised treatment in advanced breast cancer based on circulating tumour cells

At the European Cancer Congress (ECC) 2015, Wolfgang Janni, MD, PhD University Hospital Ulm, Ulm, discusses the interim analysis of the DETECT study…

The impact of the Oncotype DX® Breast Cancer Assay on the patient treatment journey

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy…

ASPIRE-PCa: Prospective, global observational study of men with late-stage prostate cancer

At the European Cancer Congress (ECC) 2015, Maria De Santis, MD, of the University of Warwick, Warwick, UK, discusses the initial results of ASPIRE-PCa…

Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse

At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a…

Biomarker-driven therapies for triple-negative breast cancer

At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups…

EMJ

Improving access to innovation in cancer care in Europe

At the European Cancer Congress (ECC) 2015, Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, describes the European School of Oncology…

Changing the standard of care in previously treated metastatic renal cell carcinoma

At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials…

POPLAR: Phase 2 trial of atezolizumab monotherapy in non-small cell lung cancer

At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy…

Biomarker analysis of coBRIM: Phase 3 trial of cobimetinib plus vemurafenib for advanced melanoma

At the European Cancer Congress (ECC) 2015, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Victoria, Australia…